menu
    • menu
    [{"orgOrder":0,"company":"ReproNovo","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Leflutrozole","moa":"Aromatase","graph1":"Endocrinology","graph2":"Phase II","graph3":"ReproNovo","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"ReproNovo \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"ReproNovo \/ Jeito Capital"},{"orgOrder":0,"company":"ReproNovo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leflutrozole","moa":"Aromatase","graph1":"Endocrinology","graph2":"Phase II","graph3":"ReproNovo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReproNovo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReproNovo \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Leflutrozole

    Menu

    Leflutrozole

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ReproNovo

                            Switzerland arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            ReproNovo

                            Switzerland arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leflutrozole Safety & Efficacy on Testicular Function with Hypogonadotropic Hypogonadism

                            Details : Leflutrozole is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hypogonadism.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ReproNovo

                            Switzerland arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            ReproNovo

                            Switzerland arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ReproNovo Secures $65M Series A to Fund Phase 2 Trials in Reproductive Medicine

                            Details : The financing aims to advance the development of the company’s lead candidate, RPN-001 (leflutrozole), focusing on an orally administered therapy for infertility in men with low serum testosterone.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 21, 2025

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 6 Month Safety Extension Study of MBGS205

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 20, 2016

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 06, 2016

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 05, 2010

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth